Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

British Journal of Cancer

Volumn 116, Issue 4, 2017, Pages 501-508

  Kazarian, Anna ^a   Blyuss, Oleg ^a   Metodieva, Gergana ^b   Gentry Maharaj, Aleksandra ^a   Ryan, Andy ^a   Kiseleva, Elena M ^c   Prytomanova, Olga M ^c   Jacobs, Ian J ^d   Widschwendter, Martin ^a   Menon, Usha ^a   Timms, John F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ESSEX   (United Kingdom)

^c OLES HONCHAR DNIPRO NATIONAL UNIVERSITY   (Ukraine)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOC1 PROTEIN; CA15 3 PROTEIN; HSP90A PROTEIN; IGFBP3 PROTEIN; PAI-1 PROTEIN; PAPPA PROTEIN; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PROGNOSIS; UNITED KINGDOM;

EID: 85009351662     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.433     Document Type: Article

References (46)

1. Baum M (2010) Should routine screening by mammography be replaced by a more selective service of risk assessment/risk management? Womens Health (Lond) 6: 71-76
2. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM (2006) Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 7: 167-174
3. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356: 227-236
4. Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Chambers AF (2014) Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res 16: R8
5. Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK (2012) Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 14: R62
6. Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC (2014) Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res 16: R63
7. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845
8. Devetyarov D, Nouretdinov I, Burford B, Camuzeaux S, Gentry-Maharaj A, Tiss A, Smith C, Luo Z, Chervonenkis A, Hallett R, Vovk V, Waterfield M, Cramer R, Timms JF, Sinclair J, Menon U, Jacobs I, Gammerman A (2012) Conformal predictors in early diagnostics of ovarian and breast cancers. Prog Artif Intell 1: 245-257
9. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M (2014) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16: 428
10. Duran MC, Vega F, Moreno-Bueno G, Artiga MJ, Sanchez L, Palacios J, Ridley A, Timms JF (2008) Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer. Proteomics Clin Appl 2: 1313-1326
11. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, Fateh-Moghadam A, Seidel D (2002) Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 86: 1217-1222
12. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066
13. Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ (1992) CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70: 2831-2834
14. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, Gatti C, Paccagnella A, Marubini E (2002) Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38: 1181-1188
15. Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC (2011) Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prev 20: 1543-1551
16. Gotzsche PC, Jorgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev 6: CD001877
17. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312
18. Hayes DF, Zurawski Jr VR, Kufe DW (1986) Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4: 1542-1550
19. Hu Y, Sun H, Drake J, Kittrell F, Abba MC, Deng L, Gaddis S, Sahin A, Baggerly K, Medina D, Aldaz CM (2004) From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res 64: 7748-7755
20. Jatoi I (1999) Breast cancer screening. Am J Surg 177: 518-524
21. Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11: 530-542
22. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW (2009) The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 11: R22
23. Kiseleva EM, Shor NZ (2005) Continuous Problems of Optimal Set Partitioning: Theory, Algorithms, Applications. Naukova Dumka: Kyiv
24. Lee HB, Kang UB, Moon HG, Lee J, Lee KM, Yi M, Park YS, Lee JW, Yu JH, Choi SH, Cho SH, Lee C, Han W, Noh DY (2015) Development and validation of a novel plasma protein signature for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry. Anticancer Res 35: 6271-6279
25. Loddo M, Andryszkiewicz J, Rodriguez-Acebes S, Stoeber K, Jones A, Dafou D, Apostolidou S, Wollenschlaeger A, Widschwendter M, Sainsbury R, Tudzarova S, Williams GH (2014) Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer. J Pathol 233: 344-356
26. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128
27. Mansfield AS, Visscher DW, Hart SN, Wang C, Goetz MP, Oxvig C, Conover CA (2014) Pregnancy-associated plasma protein-A expression in human breast cancer. Growth Horm IGF Res 24: 264-267
28. McCarthy K, Laban C, McVittie CJ, Ogunkolade W, Khalaf S, Bustin S, Carpenter R, Jenkins PJ (2009) The expression and function of IGFBP-3 in normal and malignant breast tissue. Anticancer Res 29: 3785-3790
29. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10: 327-340
30. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I (2008) Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study. BMJ 337: a2079
31. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I (2015) Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of ovarian cancer screening. J Clin Oncol 33(18): 2062-2071
32. Nauck D, Klawonn F, Kruse R (1997) Foundations of Neuro-Fuzzy systems. John Wiley &Sons: New York, NY, USA
33. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7: 285-289
34. Opstal-Winden AW, Krop EJ, Karedal MH, Gast MC, Lindh CH, Jeppsson MC, Jonsson BA, Grobbee DE, Peeters PH, Beijnen JH, van Gils CH, Vermeulen RC (2011) Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer 11: 381
35. Opstal-Winden AW, Rodenburg W, Pennings JL, van Oostrom CT, Beijnen JH, Peeters PH, van Gils CH, Vries A (2012) A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci 13: 13587-13604
36. Pace LE, Keating NL (2014) A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 311: 1327-1335
37. Paiva RP, Dourado A (2004) Interpretability and learning in neuro-fuzzy systems. Fuzzy Sets Syst 147: 17-38
38. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67: 2932-2937
39. Shao Y, Sun X, He Y, Liu C, Liu H (2015) Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One 10: e0133830
40. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29
41. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611
42. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285
43. Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jager W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I (2003) Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin Lab 49: 15-24
44. Welch HG, Prorok PC, O'Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375: 1438-1447
45. Worthington J, Bertani M, Chan HL, Gerrits B, Timms JF (2010) Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells-interplay of ErbB and IGF1 signalling through IGFBP3 regulation. BMC Cancer 10: 490
46. Zagouri F, Sergentanis TN, Provatopoulou X, Kalogera E, Chrysikos D, Lymperi M, Papadimitriou CA, Zografos E, Bletsa G, Kalles VS, Zografos GC, Gounaris A (2011) Serum levels of HSP90 in the continuum of breast ductal and lobular lesions. In Vivo 25: 669-672